- Home
- Companies
- PsiOxus Therapeutics Ltd.
- Products
- PsiOxus - Model NG-641 - Single or ...
PsiOxus - Model NG-641 - Single or Multi-Protein Therapeutics Medicine
Four transgenes: Producing an anti-FAP bispecific plus cytokines/chemokines. Currently in clinical trials in the US and UK. See our clinical trials page for more information. The aim of this study is to characterise the safety, tolerability and preliminary efficacy of NG-641 in patients with metastatic or advanced epithelial tumors.
Our approach to treating cancer involves selective delivery of single or multi-protein therapeutics to tumors via an intravenously injected viral vector. These therapeutics act locally to reprogram the tumor microenvironment, providing new treatment options for patients with cancer.
Our novel class of medicines expand the potential of immunotherapy to applications beyond T cell-rich ‘hot’ tumors, with therapeutic potential as both single agent and in combination with current immuno-oncology agents